|
1
|
Falkson CB, Bezjak A, Darling G, Gregg R,
Malthaner R, Maziak DE, Yu E, Smith CA, McNair S, et al: The
management of thymoma: A systematic review and practice guideline.
J Thorac Oncol. 4:911–919. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Eng TY, Fuller CD, Jagirdar J, Bains Y and
Thomas CR Jr: Thymic carcinoma: State of the art review. Int J
Radiat Oncol Biol Phys. 59:654–664. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
NCCN guidelines on the treatment of
thymomas and thymic carsinomas. Version 1. 2014.http://www.nccn.org/professionals/physician_gls/pdf/thymic.pdfAccessed.
July 05–2015
|
|
4
|
Desai N, Trieu V, Yao Z, Louie L, Ci S,
Yang A, Tao C, De T, Beals B, Dykes D, et al: Increased antitumor
activity, intratumor paclitaxel concentrations and endothelial cell
transport of cremophor-free, albumin-bound paclitaxel, ABI-007,
compared with cremophor-based paclitaxel. Clin Cancer Res.
12:1317–1324. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Socinski MA, Bondarenko I, Karaseva NA,
Makhson AM, Vynnychenko I, Okamoto I, Hon JK, Hirsh V, Bhar P,
Zhang H, et al: Weekly nab-paclitaxel in combination with
carboplatin versus solvent-based paclitaxel plus carboplatin as
first-line therapy in patients with advanced non-small-cell lung
cancer: Final results of a phase III trial. J Clin Oncol.
30:2055–2062. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gradishar WJ, Tjulandin S, Davidson N,
Shaw H, Desai N, Bhar P, Hawkins M and O'Shaughnessy J: Phase III
trial of nanoparticle albumin-bound paclitaxel compared with
polyethylated castor oil-based paclitaxel in women with breast
cancer. J Clin Oncol. 23:7794–7803. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Koizumi W, Morita S and Sakata Y: A
randomized Phase III trial of weekly or 3-weekly doses of
nab-paclitaxel versus weekly doses of Cremophor-based paclitaxel in
patients with previously treated advanced gastric cancer (ABSOLUTE
Trial). Jpn J Clin Oncol. 45:303–306. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Masaoka A, Monden Y, Nakahara K and
Tanioka T: Follow-up study of thymomas with special reference to
their clinical stages. Cancer. 48:2485–2492. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lemma GL, Lee JW, Aisner SC, Langer CJ,
Tester WJ, Johnson DH and Loehrer PJ Sr: Phase II study of
carboplatin and paclitaxel in advanced thymoma and thymic
carcinoma. J Clin Oncol. 29:2060–2065. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hirai F, Yamanaka T, Taguchi K, Daga H,
Ono A, Tanaka K, Kogure Y, Shimizu J, Kimura T, Fukuoka J, et al: A
multicenter phase II study of carboplatin and paclitaxel for
advanced thymic carcinoma: WJOG4207L. Ann Oncol. 26:363–368. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Koizumi T, Takabayashi Y, Yamagishi S,
Tsushima K, Takamizawa A, Tsukadaira A, Yamamoto H, Yamazaki Y,
Yamaguchi S, Fujimoto K, et al: Chemotherapy for advanced thymic
carcinoma: Clinical response to cisplatin, doxorubicin, vincristine
and cyclophosphamide (ADOC chemotherapy). Am J Clin Oncol.
25:266–268. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kanda S, Koizumi T, Komatsu Y, Yoshikawa
S, Okada M, Hatayama O, Yasuo M, Tsushima K, Urushihata K, Kubo K,
et al: Second-line chemotherapy of platinum compound plus CPT-11
following ADOC chemotherapy in advanced thymic carcinoma: Analysis
of seven cases. Anticancer Res. 27:3005–3008. 2007.PubMed/NCBI
|
|
13
|
Komatsu Y, Koizumi T, Tanabe T, Hatayama
O, Yasuo M, Okada M, Yamamoto H, Kubo K, Sasabayashi M and Tsunoda
T: Salvage chemotherapy with carboplatin and paclitaxel for
cisplatin-resistant thymic carcinoma-three cases. Anticancer Res.
26:4851–4855. 2006.PubMed/NCBI
|
|
14
|
Weide LG, Ulbright TM, Loehrer PJ Sr and
Williams SD: Thymic carcinoma. A distinct clinical entity
responsive to chemotherapy. Cancer. 71:1219–1223. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yoh K, Goto K, Ishii G, Niho S, Ohmatsu H,
Kubota K, Kakinuma R, Nagai K, Suga M and Nishiwaki Y: Weekly
chemotherapy with cisplatin, vincristine, doxorubicin and etoposide
is an effective treatment for advanced thymic carcinoma. Cancer.
98:926–931. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lucchi M, Mussi A, Ambrogi M, Gunfiotti A,
Fontanini G, Basolo F and Angeletti CA: Thymic carcinoma: A report
of 13 cases. Eur J Surg Oncol. 27:636–640. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Igawa S, Murakami H, Takahashi T, Nakamura
Y, Tsuya A, Naito T, Kaira K, Ono A, Shukuya T, Tamiya A, et al:
Efficacy of chemotherapy with carboplatin and paclitaxel for
unresectable thymic carcinoma. Lung Cancer. 67:194–197. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Maruyama R, Suemitsu R, Okamoto T, Kojo M,
Aoki Y, Wataya H, Eguchi T, Nishiyama K, Seto T and Ichinose Y:
Persistent and aggressive treatment for thymic carcinoma. Results
of a single-institute experience with 25 patients. Oncology.
70:325–329. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Leyvraz S, Henle W, Chahinian AP, Perlmann
C, Klein G, Gordon RE, Rosenblum M and Holland JF: Association of
Epstein-Barr virus with thymic carcinoma. N Engl J Med.
312:1296–1299. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schirosi L, Nannini N, Nicoli D, Cavazza
A, Valli R, Buti S, Garagnani L, Sartori G, Calabrese F, Marchetti
A, et al: Activating c-KIT mutations in a subset of thymic
carcinoma and response to different c-KIT inhibitors. Ann Oncol.
23:2409–2414. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kondo K and Monden Y: Therapy for thymic
epithelial tumors: A clinical study of 1,320 patients from Japan.
Ann Thorac Surg. 76:878–884; discussion 884–885. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Okuma Y, Hosomi Y, Takahashi S, Maeda Y,
Okamura T and Hishima T: Response to cytotoxic chemotherapy in
patients previously treated with palliative-intent chemotherapy for
advanced thymic carcinoma. Clin Lung Cancer. 16:221–227. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li W, Miao Z, Liu X, Zhang Q, Sun L, Li P,
Liu W and Zhang L: Thymic carcinoma patients with myasthenia gravis
exhibit better prognoses. Int J Clin Oncol. 2015 Jul 3;[Epub ahead
of print].
|
|
24
|
Filosso PL, Guerrera F, Rendina AE, Bora
G, Ruffini E, Novero D, Ruco L, Vitolo D, Anile M, Ibrahim M, et
al: Outcome of surgically resected thymic carcinoma: A multicenter
experience. Lung Cancer. 83:205–210. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang S, Wang Z, Liu X, Wang D and Liu F:
Prognostic factors of patients with thymic carcinoma after surgery:
A retrospective analysis of 58 cases. World J Surg. 38:2032–2038.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Makimoto G, Fujiwara K, Watanabe H,
Kameyama N, Matsushita M, Rai K, Sato K, Yonei T, Sato T and
Shibayama T: nab-Paclitaxel in combination with carboplatin for a
previously treated thymic carcinoma. Case Rep Oncol. 7:14–17. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhan P, Xie H and Yu LK: Response to
nab-paclitaxel and nedaplatin in a heavily-metastatic thymic
carcinoma: A case report. Oncol Lett. 9:1715–1718. 2015.PubMed/NCBI
|
